How many drugs treat Erythema nodosum leprosum?

Drug Landscape tracks 3 marketed treatments for Erythema nodosum leprosum (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/erythema-nodosum-leprosum.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Erythema nodosum leprosum — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erythema nodosum leprosum (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Erythema nodosum leprosum, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Thalomid	THALIDOMIDE	Bristol-Myers Squibb	thalidomide	Tumor necrosis factor	1998-01-01
Lamprene	clofazimine	Novartis	Antimycobacterial	ATP-binding cassette sub-family G member 2	1986-01-01
Thalomid	Thalomid	Ann & Robert H Lurie Children's Hospital of Chicago		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Protein cereblon

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Ann & Robert H Lurie Children's Hospital of Chicago · 1 drug in Erythema nodosum leprosum
Bristol-Myers Squibb · 1 drug in Erythema nodosum leprosum
Novartis · 1 drug in Erythema nodosum leprosum

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Erythema nodosum leprosum:

Cite this brief

Drug Landscape (2026). Erythema nodosum leprosum — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/erythema-nodosum-leprosum. Accessed 2026-06-10.

Erythema nodosum leprosum full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing